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Abstract
Type 1 diabetes (T1D) increases risk of the development of microvascular complications and cardiovascular disease (CVD).
Dyslipidemia is a common risk factor in the pathogenesis of both CVD and diabetic nephropathy (DN), with CVD identified
as the primary cause of death in patients with DN. In light of this commonality, we assessed single nucleotide
polymorphisms (SNPs) in thirty-seven key genetic loci previously associated with dyslipidemia in a T1D cohort using a case-
control design. SNPs (n = 53) were genotyped using Sequenom in 1467 individuals with T1D (718 cases with proteinuric
nephropathy and 749 controls without nephropathy i.e. normal albumin excretion). Cases and controls were white and
recruited from the UK and Ireland. Association analyses were performed using PLINK to compare allele frequencies in cases
and controls. In a sensitivity analysis, samples from control individuals with reduced renal function (estimated glomerular
filtration rate,60 ml/min/1.73 m2) were excluded. Correction for multiple testing was performed by permutation testing. A
total of 1394 samples passed quality control filters. Following regression analysis adjusted by collection center, gender,
duration of diabetes, and average HbA1c, two SNPs were significantly associated with DN. rs4420638 in the APOC1 region
(odds ratio [OR] = 1.51; confidence intervals [CI]: 1.19–1.91; P = 0.001) and rs1532624 in CETP (OR = 0.82; CI: 0.69–0.99;
P = 0.034); rs4420638 was also significantly associated in a sensitivity analysis (P = 0.016) together with rs7679 (P = 0.027).
However, no association was significant following correction for multiple testing. Subgroup analysis of end-stage renal
disease status failed to reveal any association. Our results suggest common variants associated with dyslipidemia are not
strongly associated with DN in T1D among white individuals. Our findings, cannot entirely exclude these key genes which
are central to the process of dyslipidemia, from involvement in DN pathogenesis as our study had limited power to detect
variants of small effect size. Analysis in larger independent cohorts is required.
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Introduction
Type 1 diabetes mellitus (T1D) has been previously reported to
increase the risk of microvascular complications and cardiovascu-
lar disease (CVD) [1–3]. In contrast to the reduction in
cardiovascular mortality within the general US population, the
declining trend is less evident in individuals with diabetes [4].
Despite improved disease management strategies, CVD remains
the primary cause of death in patients with T1D [5] and a ten-fold
increase in risk is reported in those with diabetic nephropathy
(DN) relative to those without it [6]. DN is a complex, multi-
factorial disease and identifying robust genetic risk factors has
proved challenging. Several risk factors are common to both CVD
and DN, including hypertension, male gender, smoking and
modifiable dyslipidemia [5–11].
Dyslipidemia results from abnormal lipid metabolism with
departure from optimum vascular cholesterol and triglyceride
levels leading to atherosclerosis, a process of fatty acid plaque
deposition in arterial blood vessels. Previous studies reported
normal low-density lipoprotein (LDL) and high-density lipoprotein
(HDL) cholesterol levels in individuals with T1D, with elevated
triglyceride levels more commonly associated with poor glycemic
control [12]. This abnormal lipid profile can result from insulin
deficiency with subsequent reduction in lipoprotein lipase activity
and diminished ability for chylomicron and very low-density
lipoprotein (VLDL) clearance [13]. This contrasts with individuals
with type 2 diabetes (T2D) who often exhibit reduced HDL levels
with a shift in LDL to the more atherogenic dense VLDL particles
as a consequence of increased hepatic production. This process is
increased by insulin resistance resulting in reduced clearance of
VLDL and chylomicrons [14].
Observational studies have identified multiple lipid abnormal-
ities in both incipient and overt DN [15–17], although this has not
been consistently reported [18]. While the exact mechanism of
effect is not fully understood, dyslipidemia has been associated
with DN progression as well as increasing cardiovascular risk [19–
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20]. Supporting evidence implicates insulin resistance as pivotal in
the development and/or progression of this condition [21–25].
Potential mechanisms contributing to renal injury in DN have
included stimulation of pro-inflammatory and pro-fibrotic cyto-
kine production, cell apoptosis, vasoconstriction and modulation
of mesangial cell proliferation [26–28]. As such, parallels between
mechanisms that underpin atherosclerosis and glomerulosclerosis
provide support for investigation of the parameters that contribute
to both conditions [29].
While previous evidence demonstrates modulation of lipid
profiles through lifestyle changes such as smoking, diet and
physical activity, recent studies have also identified common
genetic variation as regulators of lipid levels and subsequent
dyslipidemia [30–37]. To date, almost 100 genetic loci have been
reported in association with serum cholesterol and triglyceride
levels [38]. Aulchenko and colleagues highlighted that many of the
loci influencing lipid levels and CVD risk had previously been
identified in association studies enriched by participants with
diabetes [34]. The management of diabetic dyslipidemia, a well-
recognized and modifiable risk factor, is a key element in the
multifactorial approach to prevent CVD in individuals with
diabetes [23]. In light of the evidence supporting association of
these variants with dyslipidemia in individuals with diabetes, we
sought to assess the allelic frequency of 53 common single
nucleotide polymorphisms (SNPs) in 37 key loci in individuals with
DN using a case-control design involving 1467 individuals with
T1D. These loci and SNPs were selected on the basis of their
functional significance and previous reported association with
dyslipidemia [30–37].
Methods
Participants
Research ethics approval was obtained from the South and
West Multicentre Research Ethics Committee (MREC/98/6/71)
and Queens University Belfast Research Ethics Committee.
Written informed consent was obtained prior to participation.
All recruited individuals were white, had T1D diagnosed before
32 years of age and were born in the UK or Ireland. Patients
(n = 718) and controls (n = 749) originated from the Warren 3/UK
Genetics of Kidneys in Diabetes (GoKinD) and all-Ireland
collections [39]. The definition of DN in cases was based on
development of persistent proteinuria (.0.5 g protein/24 h) at
least 10 years after diagnosis of T1D, hypertension (blood pressure
.135/85 mmHg or treatment with antihypertensive agents) and
associated diabetic retinopathy. Controls were individuals with
T1D for at least 15 years with normal urinary albumin excretion
rates and no evidence of microalbuminuria on repeated testing. In
addition, control subjects had not been prescribed antihyperten-
sive drug treatment avoiding possible misclassification of diabetic
individuals as ‘control phenotypes’ when the use of antihyperten-
sive treatment may have reduced urinary albumin excretion into
the normal range. Individuals with microalbuminuria were
excluded from both case and control groups since it was not
possible to be confident in assigning case/control status for such
individuals whose urinary albumin excretion might either regress
or progress over time [40].
SNP selection and genotyping
SNPs (n = 53) were selected on the basis of previously reported
association with dyslipidemia [31–34] and of minor allele frequency
(MAF) exceeding 0.1 in populations of European descent. Geno-
typing was performed by MassARRAY iPLEX (Sequenom, San
Diego, CA, USA) assays according to the manufacturer’s instruc-
tions. Quality filters for exclusion of SNPs included call rates below
95% and deviation from HWE (P,0.001). DNA samples were
excluded if missing genotypes exceeded 10%. Other quality control
measures included parent/offspring trio samples, duplicates on
plates, random sample allocation to plates, independent scoring of
Table 1. Clinical characteristics of diabetic nephropathy (DN) cases and no nephropathy diabetic controls.
Characteristic DN cases (n=718) Controls (n =749) P value
Male; n (%) 415 (57.8%) 320 (42.7%) ,0.001
Age at diagnosis of T1D (yr) 14.867.7 15.567.9 0.09
Duration of T1D (yr)a 33.369.4 28.169.0 ,0.001
Age at sampling 48.1610.4 43.6611.0 ,0.001
HbA1c (%)b 9.061.9 8.661.5 ,0.001
Systolic blood pressure (mmHg)b 144.9620.9 125.0614.7 ,0.001
Diastolic blood pressure (mmHg)b 81.5611.4 75.467.8 ,0.001
Body mass index (kg/m2) 26.364.7 26.164.2 0.50
Serum cholesterol (mmol/L) 5.3461.22 5.0960.91 ,0.001
HDL cholesterol (mmol/L) 1.5960.55 1.7860.47 ,0.001
LDL cholesterol (mmol/L) 2.8860.95 2.8060.75 0.17
Serum triglycerides (mmol/L) median (interquartile range) 1.4 (1.0–2.2) 1.0 (0.7–1.4) ,0.001
Serum creatinine (mmol/L);c median (interquartile range) 130 (102–183) 92 (79–105) ,0.001
Estimated glomerular filtration rate (ml/min/1.73m2);c median (interquartile range) 48 (33–66) 70 (59–85) ,0.001
End-stage renal disease; n (%) 193 (26.9%) NA NA
Passed quality control criteria; n (%) 684 (95.3%) 710 (94.8%) 0.68
Unless otherwise stated values are mean 6 standard deviation.
aCalculated from the dates of diagnosis and recruitment.
bAverage of the three most recent values prior to recruitment.
cExcludes subjects receiving renal replacement therapy (dialysis or transplant).
doi:10.1371/journal.pone.0058472.t001
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problematic genotypes by two individuals and re-sequencing of
selected DNAs to validate genotypes.
Statistical analysis
Clinical characteristics of cases and controls were compared using
the z-test for large independent samples and the x2 test. Association
analyses were performed using PLINK (version 1.07; http://pngu.
mgh.harvard.edu/,purcell/plink/). Initially ax2 test for trend (1 df)
was used with stratification by collection center. Logistic regression
analysis was performed on each SNP with terms for potential
confounders (collection center, gender, duration of T1D and
HbA1c) included in the model. A sensitivity analysis to minimize
potential misclassification of case/control status was performed by
excluding samples from those control individuals with an estimated
glomerular filtration (eGFR) ,60 ml/min/1.73 m2. The level of
statistical significance was set at 5% and adjustment for multiple
testing performed by permutation test (n = 100,000). Potential gene-
gene interactions between SNPs were assessed using likelihood ratio
x2 tests in the logistic regression with terms for potential confounders
(collection center, gender, duration of T1D and HbA1c) included in
the model.
Results
The clinical characteristics of the DN cases (n = 718) and
diabetic controls (n = 749) genotyped in this study are listed in
Table 1. There were more males, higher mean HbA1c and blood
pressure values (despite the use of antihypertensive treatment) in
the case group compared with the control group. All comparisons
were significant at P,0.001 with the exception of age at diagnosis,
LDL cholesterol and body mass index which did not differ
significantly between groups. Approximately one quarter of cases
(26.9%) had end-stage renal disease (ESRD).
A total of 53 SNPs were genotyped using MassARRAY iPLEX
technology in 718 cases and 749 controls (Table 2). We excluded
73 samples (34 cases and 39 controls) from the analysis with$10%
missing genotypes. The average call rate for all SNPs analysed was
99.3%. The genotype distribution for each SNP did not deviate
significantly from HWE in either cases or controls. No duplicate or
Mendelian inconsistencies were observed.
Single marker testing stratified by collection center identified
two non-coding SNPs (rs1532624 in Cholesteryl ester transfer
protein (CETP) and rs4420638 in Apolipoprotein C-I APOC1) to
be significantly associated with DN (Table 2). In logistic regression
analysis with adjustment by collection center, gender, duration of
T1D, and average HbA1c as covariates, the significance of both
SNPs was maintained (rs1532624: odds ratio [OR] = 0.82;
confidence intervals [CI]: 0.69–0.99; P = 0.034; rs4420638:
OR = 1.51; CI: 1.19–1.91; P = 0.001). The sensitivity analysis
(that includes samples only from those controls with eGFR
.60 ml/min/1.73 m2) identified two SNPs significantly associat-
ed with DN in the fully adjusted model (rs4420638; P = 0.016 and
rs7679; P = 0.027). However, no associations were maintained
following correction for multiple testing. Subgroup analyses
showed no association of any SNP with ESRD status.
With no prior hypotheses or supporting evidence of potential
gene-gene interaction, we assumed a more stringent level of
significance (P,0.01). Interactions were assessed using likelihood
ratio x2 tests in the logistic regression with terms for potential
confounders (collection center, gender, duration of T1D and
HbA1c) included in the model. Seven interaction terms exceeded
the minimum threshold set but following correction for multiple
testing and examination of the resultant Q-Q plot, none were
identified as being worthy of further investigation (Table 3).
Discussion
Dyslipidemia can result through dietary and lifestyle influences
or alternatively as a consequence of variation in genes pivotal to
lipoprotein metabolism. In persons with diabetes, prolonged
elevation of insulin levels often leads to dyslipidemia, a process
central to the pathogenesis of atherosclerosis and increasing CVD
risk. As previous studies have reported multiple lipid abnormalities
in patients with T1D [15–20], we evaluated common polymorphic
variation previously associated with dyslipidemia, in persons with
T1D, both with and without DN. Univariate analysis identified
two SNPs associated with DN (rs1532624 in CETP and rs4420638
in APOC1) both of which remained significant following adjust-
ment for collection center, gender, duration of T1D, and average
HbA1c. Interestingly, rs4420638 was also significantly associated
with DN in the sensitivity analysis using only those samples from
diabetic controls with eGFR .60 ml/min/1.73 m2. However,
following correction for multiple testing, these associations were no
longer significant. Although, published data were available from
the US GoKinD genome-wide association study, limited coverage
on the Affymetrix 500 K genotyping platform across the genomic
locations of both CETP and APOC1, prevented in silico indepen-
Table 4. Study power to detect various odds ratios for
selected minor allele frequencies.
Odds Minor Allele Frequency (MAF)
ratio 0.10 0.20 0.30 0.40
1.2 30% 49% 59% 65%
1.3 56% 81% 89% 92%
1.4 79% 96% 99% 99%
1.5 93% 99% 100% 100%
Power calculations are based on 684 cases and 710 controls with odds ratio
ranging from 1.2–1.5 for SNPs with a MAF between 0.10 and 0.40 with no
correction for multiple testing.
doi:10.1371/journal.pone.0058472.t004
Table 3. Assessment of gene-gene pair-wise interactions.
SNP 1 Gene 1 SNP 2 Gene 2 1P value 2P value
rs3905000 ABCA1 rs7679 PCIF1 0.002 0.014
rs6756629 ABCG5 rs714052 BAZ1B 0.003 0.009
rs2240466 BAZ1B rs6756629 ABCG5 0.007 0.01
rs2240466 BAZ1B rs12678919 LPL 0.007 0.115
rs1167998 DOCK7 rs17216525 CILP2PBX4 0.008 0.002
rs10903129 TMEM57 rs6544713 ABCG8 0.009 0.024
rs12678919 LPL rs714052 BAZ1B 0.009 0.14
The number of significant interactions observed is less than one might expect
by chance.
P values for gene-gene interactions were obtained between SNPs using
likelihood ratio x2 tests in the logistic regression. Data are presented for those
which attained significance at the P,0.01 level in an unadjusted model1.
Significance levels are also presented where terms for potential confounders
(collection center, gender, duration of T1D and HbA1c) are included in the
adjusted model2.
doi:10.1371/journal.pone.0058472.t003
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dent replication or meta-analysis of our top SNPs or any potential
proxies (r2.0.8) [41].
In previously published studies the definition of the DN
phenotype has proved challenging. We do not think it is surprising
that cases in our study had persistent proteinuria (macroalbumin-
uria) despite the use of antihypertensive medication. The use of
angiotensin converting enzyme inhibitors (ACEi) or angiotensin
receptor blockers (ARBs), typically reduces but does not abolish
protein excretion in persons with overt diabetic nephropathy [42–
44] suggesting that persistent proteinuria is unlikely to be a
consequence of suboptimal blood pressure control. The differences
in mean blood pressures observed between case and control
groups were consistent with findings in clinical practice.
In addition, it has been suggested that some individuals with a
very prolonged duration of type 1 diabetes may develop chronic
kidney disease (CKD) without albuminuria. Molitch and col-
leagues [45] identified 89 of the 1,439 individuals recruited to the
DCCT/EDIC study that had developed CKD (defined by
estimated GFR ,60 ml/min/1.73 m2) after almost 20 years of
follow up. Of the 89 individuals with CKD, 21 were classified as
normoalbuminuric (albumin excretion rate [AER] ,30); 14 as
microalbuminuric (AER: 30–300); and 54 as macroalbuminuric
(AER .300). Of note 43% of the normoalbuminuric individuals
with CKD were taking ACEi during the study and 14% were
taking ARBs at year 13/14 of the EDIC study [45]. The
antihypertensive drugs, ACEi and ARBs, can both lower AER and
reduce eGFR which may partly explain why the authors found a
small number of individuals with normoalbuminuria and reduced
eGFR. The normoalbuminuric patients with reduced eGFR were
also 4 years older at time of recruitment than the macroalbumi-
nuric patients (30+/27 yr vs. 26+/2 7 yr [45]). Nevertheless, we
did attempt to address this issue of diabetic patients having CKD
without albuminuria. In a sensitivity analysis, we excluded all those
diabetic patients we had originally recruited as normalbuminuric
controls in whom the eGFR was ,60 ml/min/1.73 m2. We
excluded these controls with reduced renal function from our
analysis to limit any risk of misclassification of nephropathy status
but found this made little difference to the main analysis (Table 2).
CETP is a protein central to the process of dyslipidemia. It acts
as a mediator for the transfer of cholesteryl esters from HDL to
VLDL or LDL in exchange for triglycerides, reducing serum HDL
concentrations [46]. Variation in CETP levels have been
correlated with lipid metabolism and insulin resistance in Type
2 diabetes [47], and also in association with the development of
obesity [48] and susceptibility to atherosclerosis and other CVD
[49]. Recently, Igl and colleagues demonstrated that the genetic
influence mediated by rs1532624 could be attenuated by lifestyle
factors such as diet or physical activity, highlighting the potential
for interaction at this locus [50]. Our study was unable to examine
lifestyle influences, as dietary and physical activity measurements
were not collected during recruitment. Nonetheless we sought to
evaluate the potential for pair-wise gene-gene interaction between
the candidate SNPs examined. Several pair-wise interactions
which included the CETP and APOB loci were identified but did
not remain significant following correction for multiple testing. As
no association survived correction for multiple testing, it is unlikely
these gene variants play a specific role in the etiology of DN.
Apo C-I is a protein constituent of chylomicrons, VLDL and
HDL and while its precise physiological role is not well established,
evidence has demonstrated support for its involvement in HDL
metabolism through activation and inhibition of other proteins
central to lipid metabolism, including CETP [51]. Association of
rs4420638 with DN in T1D in this cohort has been previously
reported [52].
Improved therapeutic regimens to lower LDL levels using
statins have proved beneficial for patients both with and without
diabetes with respect to CVD risk. In addition, increasing evidence
suggests statins provide therapeutic benefit independent of
cholesterol modulation, by improving endothelial and vascular
function and reducing inflammation [53].
Common genetic loci explain only a proportion of the variation
observed in lipid levels within the general population. Evidence in
support of rare variants with potentially large individual effect size
continues to grow, and is likely to make a significant impact on the
genetic heritability of this condition [36]. Since our study focused
only on common variants, untyped, highly penetrant rare variants
in these genes could also contribute to DN. This study has
insufficient power to detect rare variants particularly if the effect
sizes are small in magnitude, such as the odds ratios of 1.2/1.3
which are more commonly found in common complex diseases
(Table 4). Future amalgamation of independent cohorts with
similar DN phenotypes will enable a more robust evaluation of
such loci. In addition, other factors such as copy number variation
or indeed epigenetic mechanisms (e.g. DNA methylation, histone
modification and microRNAs) may also attenuate gene function
affecting these pathways which modulate disease risk.
Although the SNPs assessed in this study were chosen on the basis
of previous associations with dyslipdemia there are a number of
inherent limitations associated with using 53 SNPs across 37 genes
[54]: (1) identification of association does not necessarily equate to
functional significance given the concept of linkage disequilibrium
(LD). (2) assessing one or two SNPs per gene may provide inadequate
representation of the genetic architecture at that locus. (3) patterns of
LD can vary significantly within and between different populations
and therefore a significant association in one population may not
necessarily translate across all populations.
In conclusion, we found no strong association between common
variants in genes involved in dyslipidemia and DN. Further work
to investigate lifestyle factors which influence genes may identify
potential risk factors for susceptibility to DN.
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